Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Homerun Slides: Clinical presentation library Previous | All Articles This Week | Next
This article originally posted 02 July, 2012 and appeared in  Medication Slides, GLP-1 Receptor Agonist Therapy, Diabetes Clinical Mastery Series Issue 91, SGLT2

Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 1 of 2

DCMS91HS 

Part 1 of this two-part series covers some of the newest therapies for type 2 diabetes including GLP-1 agonists and DPP-4 inhibitors. We also take a look at some of the even newer therapies on the horizon such as SGLT2 inhibitors, ultra long-acting insulin (degludec) and interleukin-1 blocker, diacerein. 

Link to download (.ppt format): Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 1 of 2.

Other sets in this series:

Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 2 of 2

Check out all of Diabetes In Control's slide collections at our Clinical Presentations Library.

Related Articles

Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 2 of 2 AACE: Ralph A. DeFronzo, MD -- Diabetes Prevention Supports More Aggressive and Earlier Intervention Diabetes Update, Part 3 of 3
Advertisement

 

Bookmark and Share | Print | Category | Home

This article originally posted 02 July, 2012 and appeared in  Medication Slides, GLP-1 Receptor Agonist Therapy, Diabetes Clinical Mastery Series Issue 91, SGLT2

Past five issues: Diabetes Clinical Mastery Series Issue 141 | Issue 681 | Diabetes Clinical Mastery Series Issue 140 | Issue 680 | Diabetes Clinical Mastery Series Issue 139 |

2013 Most Popular Articles:

Mortality Risk in Patients with Type 2 Diabetes
Posted May 23, 2013
 Bacteria in the Gut Improves the Management of Obesity and Type 2 Diabetes
Posted May 23, 2013
 Hypoglycemia Treatment and Prevention Related to Physical Activity
Posted May 31, 2013
 Scientist Use Bone Marrow Stem Cells to Cure Type 1 Diabetes
Posted June 06, 2013
 Simvastatin Can Reduce the Benefits of Exercise in Active Adults
Posted May 23, 2013
 Diabetes Epidemic Growing
Posted May 23, 2013
 Co-Q10 May Offset Risk of Diabetes with Statin Use
Posted May 23, 2013
 Artificial Sweeteners May Affect Blood Glucose Levels and Insulin Response
Posted June 06, 2013
 FDA Advisory Panel Votes to Remove Avandia's Highly Restrictive Label
Posted June 06, 2013
 Pros and Cons of Incretin-Based Therapies
Posted May 30, 2013
See more most popular…


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |
 
Diabetes In Control Advertisers
 
Cast Your Vote
If the FDA relaxes prescribing restrictions on Avandia, will you recommend it?

Navigate Diabetes In Control

Cardiovascular CE & CME Clinical Slides Drugs Affecting BG Safety Tools Test Your Knowledge Medications Polls Obesity Case Studies Jobs Interviews GLP-1 Agonist Sheri R. Colberg, PhD SGLT-2

 

Free Weekly Newsletter
Sign up here.

Free CE Available
CE Programs on diabetes




Search Articles On Diabetes In Control